Clomipramine for panic disorder: I. the first 10 weeks of a long-term comparison with imipramine

Cassano, Gb; Petracca, A.; Perugi, Giulio; Nisita, C.; Musetti, Laura; Mengali, Francesco; McNair, Douglas M.

doi:10.1016/0165-0327(88)90054-7

Cited by 67 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very few trials, however, have investigated the efficacy of the other TCAs in panic disorder. Two comparative studies have shown that clomipramine is at least as effective as imipramine [Modigh et al, 1992;Cassano et al, 1988], while lofepramine [Fahy et al, 1992] demonstrated comparable efficacy to clomipramine in a placebo-controlled trial. Desipramine showed significant improvement in some, but not all, efficacy measures of panic disorder in a placebo-controlled trial [Lydiard et al, 1993]; the tetracyclic antidepressant, maprotiline, has been reported to be ineffective [den Boer and Westenberg, 1988].…”

Section: Treatment Options In Panic Disordermentioning

confidence: 97%

Management of anxiety disorders: The added challenge of comorbidity

Dünner

2001

Depress. Anxiety

View full text Add to dashboard Cite

Patients with anxiety present with a wide variety of disorders that cause significant impairment to their everyday lives. To complicate matters, patients seldom present with just one anxiety disorder. Such comorbidity, particularly where depression is also present, has important implications for both the patient and the physician. The patient typically suffers from a greater degree of everyday impairment, is more reliant on healthcare services, in particular mental health services, and may be at a greater risk of attempting suicide. For the physician, comorbidity in anxiety disorders presents a challenge as the patient's symptoms are often more severe, present earlier in life, and are frequently prolonged which makes their management more complex. This review will focus on the anxiety disorders: panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorder. The impact of co-existing multiple anxiety disorders, depression, or a history of substance abuse will be discussed with a view to choosing the appropriate management strategy. Treatment options will be reviewed.

show abstract

Section: Treatment Options In Panic Disordermentioning

confidence: 97%

Management of anxiety disorders: The added challenge of comorbidity

Dünner

2001

Depress. Anxiety

View full text Add to dashboard Cite

show abstract

“…In a 26-week long-term study, it was as effective as fluoxetine (Amore et al 1999a) (A). Á Clomipramine also showed efficacy in DBPC Johnston et al 1988) and comparator-controlled studies (Cassano et al 1988;Fahy et al 1992;Modigh et al 1992;Wade et al 1997).…”

Section: Tricyclic Antidepressants (Tcas) Treatment Withmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

712

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

“…Avoidance behaviour was also reduced in the patients with agoraphobia with panic attacks without any specific behaviour therapy programme. Cassano et al, (1988) compared clomipramine and imipramine in the treatment of panic attacks over 10 weeks and found both drugs effective. There was a small non-significant advantage for clomipramine over imipramine in alleviating panic.…”

Section: Discussionmentioning

confidence: 98%

A short‐term open trial of clomipramine in the treatment of patients with panic attacks

Judd

Burrows

Marriott

et al. 1991

Human Psychopharmacology

View full text Add to dashboard Cite

Clomipramine was used to treat 14 patients with panic attacks. Diagnosis was made according to DSM-111 criteria for agoraphobia with panic attacks or panic disorder uncomplicated. An open evaluation of the drug over an 8-week treatment period was conducted. A total of 10 patients completed the study. Clomipramine was effective in reducing the mean number of panic attacks, the greatest response being observed in the first 2 weeks of treatment. Findings on all outcome measures showed that clomipramine was also effective in alleviating depression secondary to panic attacks, non-specific aspects of anxiety and improving phobic avoidance. There was a suggestion that responders to treatment received lower doses of clomipramine than non-responders. Further studies are required to evaluate this issue and the role of clomipramine in the treatment of panic disorders.

show abstract

Clomipramine for panic disorder: I. the first 10 weeks of a long-term comparison with imipramine

Cited by 67 publications

References 9 publications

Management of anxiety disorders: The added challenge of comorbidity

Management of anxiety disorders: The added challenge of comorbidity

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

A short‐term open trial of clomipramine in the treatment of patients with panic attacks

Contact Info

Product

Resources

About